Resveratrol is a selective human cytochrome P450 1A1 inhibitor
about
Influence of light on aryl hydrocarbon receptor signaling and consequences in drug metabolism, physiology and diseaseCurcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast CancerAnticancer Molecular Mechanisms of ResveratrolThe molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessityHuman Cytochrome P450 1A1 Structure and Utility in Understanding Drug and Xenobiotic MetabolismPhytoestrogens and breast cancer prevention: possible mechanisms of actionRole of the modulation of CYP1A1 expression and activity in chemopreventionA synergetic screening approach with companion effector for combination therapy: application to retinoblastomaResveratrol protects mouse oocytes from methylglyoxal-induced oxidative damageCo-administration of resveratrol and lipoic acid, or their synthetic combination, enhances neuroprotection in a rat model of ischemia/reperfusionSummary of information on human CYP enzymes: human P450 metabolism data.Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injuryCancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics.Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1.Cytochrome P450 family 1 inhibitors and structure-activity relationships.Resveratrol, a phenolic antioxidant with effects on blood platelet functions.Pyranoflavones: a group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals.Effect of phytochemical intervention on dibenzo[a,l]pyrene-induced DNA adduct formationSubchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity.Oncogenicity evaluation of resveratrol in p53(+/-) (p53 knockout) mice.An alternative mode of action of endocrine-disrupting chemicals and chemoprevention.Co-treatment with indole-3-carbinol and resveratrol modify porcine CYP1A and CYP3A activities and expression.Effects of cow ghee (clarified butter oil) & soybean oil on carcinogen-metabolizing enzymes in rats.Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene.Resveratrol inhibits benzo[a]pyrene-DNA adduct formation in human bronchial epithelial cellsPreferential induction of cytochrome P450 1A1 over cytochrome P450 1B1 in human breast epithelial cells following exposure to quercetin.Pilot study of resveratrol in older adults with impaired glucose tolerance.Drug interactions involving ethanol and alcoholic beverages.Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes.Comparison of effect of resveratrol and vanadium on diabetes related dyslipidemia and hyperglycemia in streptozotocin induced diabetic ratsIs the use of resveratrol in the treatment and prevention of obesity premature?The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges.Drug interaction potential of resveratrol.Anticarcinogenic Effects of Dietary Phytoestrogens and Their Chemopreventive Mechanisms.A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives.Therapeutic Potential and Molecular Targets of Piceatannol in Chronic Diseases.Effects of resveratrol and irradiation upon oral squamous cell carcinoma cells.Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1.
P2860
Q23919671-A0289245-10FF-4AC0-A8D1-3C56D1B43E90Q26744566-4548421D-86AB-4845-85E9-BD5BAFC63284Q26752323-39EF6729-018A-4047-BDA9-63B6FA36E749Q27021258-5E963148-40D6-4EA6-BA55-6EC83B65401DQ27676875-CF821175-BF0B-4DC0-80CE-B36FAB87185DQ28276620-A6724B76-D2E3-4DA4-823C-FEC90AFDE1F0Q28307748-D90465ED-ACFB-4238-9B2A-76C1B9AE4C52Q28488349-D2AE3736-9459-4CF1-8319-CA2524B47EBFQ28534607-B7E16327-BAA0-473C-818E-6FA32FF99CE6Q28539408-D4019258-9F25-4B9A-B85C-35E783340EA1Q32103802-94940D10-11AE-4F45-9B08-C8112C6FB2DBQ34145737-E5F3246F-D675-4855-B6D4-F5ACC4F8C375Q34153260-B81B494A-DC2F-4FFE-9718-92F188D7ADD0Q34289529-BA052EFF-2DC4-4A01-B018-891C9A8E96DEQ34436975-C92147B4-AFA7-46DC-ACD8-0357AA976C1DQ34559219-6D288213-6E71-439C-9D4F-276191D15292Q34677757-A6676B4A-950A-44D9-A0A2-A3F6B1E96E33Q35015993-40E1ACB5-A40D-4827-9F22-66347B1F1A59Q35042398-25995C33-BA92-4D45-AF09-E96B8C464366Q35470480-F9E0E059-5D66-4E5E-8F6C-3D38C631D6DDQ35570811-7C6A5DE1-C84B-4F08-BC04-1D2D8B5178B6Q35758133-245061A8-805B-4070-9457-C33F3C0669A4Q35977805-1575BED5-9079-4F4F-9AAA-43C5EF142E36Q36313788-7EE02096-5104-4F4D-BD38-A5FF23B38D57Q36436327-1915847C-154A-4B4B-80BE-0AE4986C3D4BQ36694528-FCD7C033-98E2-49E8-A26D-217F1DFE9E5AQ36695365-2BFE3F4B-B6B2-42BD-9488-A7F654D4F1B0Q36871537-1AAB9DAF-DA76-47DB-A103-CC53AD6002F7Q36895103-49FE3C35-78AB-4150-9DC7-E0BF805AE063Q36960553-66E27F07-BA39-4836-8BAC-08E9EBEFE6EEQ37227343-B4558FF6-639B-4A2A-8773-9091CDA82768Q37354724-B75E2695-D7A7-4F7A-AB5A-1B8F8CF87BC8Q37601527-ED5F4CDE-28F1-4678-B5E5-2A23B8CEF150Q37826817-846AB261-D38A-4338-91AD-828842BEDAF3Q38025685-1B6CE650-637E-4E4B-8450-0CAE6C90CA65Q38495331-FF732493-1617-48B9-BFA5-85ACD22CB9BCQ38588143-9F379B9F-3054-40FA-B35E-7EC7273A9BBCQ38965212-FB4B7FF3-07FD-442C-B47C-8340E9197122Q39031115-AB3F04C0-7D7D-491E-AD19-6AB120D17136Q42717283-475D3A7A-EC67-4B15-8843-9AB461544A74
P2860
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@ast
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@en
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@nl
type
label
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@ast
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@en
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@nl
prefLabel
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@ast
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@en
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@nl
P2093
P3181
P356
P1476
Resveratrol is a selective human cytochrome P450 1A1 inhibitor
@en
P2093
P3181
P356
10.1006/BBRC.1999.1152
P407
P577
1999-08-19T00:00:00Z